CI-1033, a pan-erbB tyrosine kinase inhibitor
WJ Slichenmyer, WL Elliott, DW Fry�- Seminars in oncology, 2001 - Elsevier
Overexpression of the erbB family of receptor tyrosine kinases has been implicated in a
variety of tumors including breast, lung, prostate, and brain. Most solid tumors express one
or more of these receptors, which can often be related to tumor aggressiveness and poor
patient prognosis. CI-1033, a pan-erbB tyrosine kinase inhibitor, is a clinically promising
agent that is active against all four members of the erbB receptor tyrosine kinase family. In
vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and�…
variety of tumors including breast, lung, prostate, and brain. Most solid tumors express one
or more of these receptors, which can often be related to tumor aggressiveness and poor
patient prognosis. CI-1033, a pan-erbB tyrosine kinase inhibitor, is a clinically promising
agent that is active against all four members of the erbB receptor tyrosine kinase family. In
vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and�…
Showing the best result for this search. See all results